GNA13 (α subunit of a heterotrimeric G-protein), which can stimulate expression of CXCL5 via NF-κB pathway, becomes a novel therapeutic target due to the effect of this chemokine on prostate cancer [60]. The gene discussed is CXCL5; the disease is prostate cancer.